Clinical trial G1T48-01
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination with Palbociclib in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer (G1T48-01)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | G1 Therapeutics |
| EudraCT Identifier | 2017-004502-17 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03455270 |
| Inclusion criteria | Any line/ ER positive/ HER2 negative/ RECIST 1.1 |
| Last update |